Menu

Cell Lines Gain Cancer-Related Mutations

A screen of human embryonic stem cell lines finds several that accumulated changes in the gene TP53, including aberrations commonly seen in cancer.

Apr 27, 2017
Kerry Grens

ISTOCK, SELVANEGRAAmong 140 human embryonic stem cell lines used for basic research or clinical development, five have gathered mutations in the tumor suppressor gene TP53, according to the results of a screen published yesterday (April 26) in Nature. As STAT News reported, two of these lines—H1 and H9—have been used in people, but there is no evidence they have caused cancer in the recipients.

“Our findings indicate that an additional series of quality control checks should be implemented during the production of stem cells and their downstream use in developing therapies,” coauthor Kevin Eggan of Harvard University said in a press release. “Fortunately, these genetic checks can be readily performed with precise, sensitive, and increasingly inexpensive sequencing methods.”

The six mutations that Eggan’s team uncovered in TP53 affect regions of the p53 protein’s DNA binding region, which is commonly disrupted in human cancers.

Cells bearing the mutations appeared to have an advantage over others, the scientists showed. “My own lab first reported P53 mutations in human pluripotent stem cells two years ago, and found that they were the result of ‘evolution in a culture dish’—selection of the fittest cells in populations of cells over time,” Jeanne Loring, director of the Center for Regenerative Medicine at the Scripps Research Institute who was not part of the present study, told The San Diego Union-Tribune in an email.

“I’ve been on this quality control soapbox for so long all by myself that I’m surprised to find company,” she added. “But I’m glad that researchers are taking these issues seriously. The FDA [US Food and Drug Administration] doesn’t require genome sequencing, but we’re doing it anyway.”

January 2019

Cannabis on Board

Research suggests ill effects of cannabinoids in the womb

Marketplace

Sponsored Product Updates

Horizon Discovery extends CRISPR Screening Service to primary human T cells
Horizon Discovery extends CRISPR Screening Service to primary human T cells
Horizon Discovery Group plc (LSE: HZD) (“Horizon” or “the Company”), a global leader in gene editing and gene modulation technologies, today announced the extension of its CRISPR Screening Service to includeex vivoT lymphocytes. The service extension meets the requirements of immunology-based research in drug discovery,enabling new gene targets to be identified in biologically and potentially therapeutically relevant settings.
pIC50: The Advantages of Thinking Logarithmically
pIC50: The Advantages of Thinking Logarithmically
Watch this webinar from Collaborative Drug Discovery to learn about how using pIC50 helps you get a better sense of the relative potencies, calculate the correct mean of multiple values, and select better sampling doses.
WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
INTEGRA Biosciences is offering labs the chance to win a VIAFLO 96/384 pipette. Designed to simplify plate replication, plate reformatting or reservoir-to-plate transfers, the VIAFLO 96/384 allows labs without the space or budget for an expensive pipetting robot to increase the speed and throughput of routine tasks.
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX has announced that their digital PCR assets, including the CONSTELLATION® series of instruments, is being acquired by QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) for up to $260 million ($125 million upfront payment and $135 million of milestones).  QIAGEN has announced plans for a global launch in 2020 of a new series of digital PCR platforms that utilize the advanced dPCR technology developed by FORMULATRIX combined with QIAGEN’s expertise in assay development and automation.